Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Starpharma Commences Phase 2 Bacterial Vaginosis Study of VivaGelŽ

Abstract:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the commencement of its phase 2 study of VivaGelŽ for the treatment of bacterial vaginosis (BV), following receipt of ethics approval.

Starpharma Commences Phase 2 Bacterial Vaginosis Study of VivaGelŽ

Melbourne, Australia | Posted on August 16th, 2010

Starpharma announced in July 2010 that the US Food and Drug Administration (FDA) had accepted and cleared its investigational new drug application (IND) for the study. Clinical trial sites in the US will be initiated this week and will commence enrolment of participants immediately.

This phase of the clinical program will investigate the treatment of BV with a once daily for seven days treatment of VivaGelŽ and its findings will guide further investigation of its use in both treatment and suppression of recurrence.

BV is the most common vaginal infection worldwide, and the most common cause of vaginal irritation, discharge and malodor. It is particularly prevalent in the US, where it affects an estimated one-third of the adult female population. The condition is implicated in pelvic inflammatory disease and may also be associated with an increased risk of sexually transmitted infections, including HIV, and pre-term birth.

Dr Jackie Fairley, Chief Executive Officer of Starpharma, said: "The commencement of this study is an important step in the development of VivaGelŽ. Experts in this field have indicated there is a desperate need for new treatment options for BV."

VivaGelŽ is also being developed as a topical microbicide for the prevention of HIV and genital herpes and as a condom coating in collaboration with SSL International. Other indications are also under assessment, including prevention of human papillomavirus, and other STIs.

Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

####

About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and otherapplications. SPL has two operating companies, Starpharma Pty Ltd inMelbourne, Australia and DNT, Inc in the USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA.

For more information, please click here

Contacts:
Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © Starpharma

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Pixelligent Launches New PixClearŽ Light Extraction Materials for OLED Lighting August 4th, 2015

The annual meeting on High Power Diode Lasers & Systems will be held as part of the Enlighten Conference, October 14th & 15th August 4th, 2015

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

World's quietest gas lets physicists hear faint quantum effects August 4th, 2015

Ethics

March 2016; 6th Int'l Conference on Nanostructures in Iran July 29th, 2015

PETA science consortium to present at Society for Risk Analysis meeting December 10th, 2014

PETA science consortium experts to present at international nanotechology workshop: PETA International Science Consortium, Ltd., Is a Sponsor of Nano Risk Analysis II September 12th, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

Govt.-Legislation/Regulation/Funding/Policy

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

Small tilt in magnets makes them viable memory chips August 3rd, 2015

Vaccine with virus-like nanoparticles effective treatment for RSV, study finds August 3rd, 2015

MIPT researchers clear the way for fast plasmonic chips August 3rd, 2015

Nanomedicine

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

Artificial blood vessels become resistant to thrombosis August 4th, 2015

Nanoparticles used to breach mucus barrier in lungs: Proof-of-concept study conducted in mice a key step toward better treatments for lung diseases August 3rd, 2015

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Announcements

Artificial blood vessels become resistant to thrombosis August 4th, 2015

Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015

Proving nanoparticles in sunscreen products August 4th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Nanobiotechnology

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project